Pacira(PCRX) Prnewswire·2025-02-13 10:45Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, crucial for its product Exparel, was ruled invalid by the court, impacting approximately 80% of the company's revenue [1]. - The invalidation raises concerns about the validity of other patents held by Pacira, potentially allowing more generic competitors to enter the market [1]. Stock Performance - Following the announcement of the patent ruling, Pacira's stock price plummeted from 11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2].